Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study

Re, McLendon; Hs, Friedman; He, Fuchs; Le, Kun; Sh, Bigner

doi:10.1046/j.1365-2559.1999.00577.x

Cited by 38 publications

(26 citation statements)

References 48 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, in contrast to other pediatric solid tumors, there are no well-defined pathologic criteria to subclassify medulloblastomas with respect to prognosis. Consequently, several studies have searched for potential immunohistochemic markers 29 as well as genetic markers associated with good or poor prognosis. 30 Coexpression of HER2 and HER4, two members of the epidermal growth factor receptor family, showed independent prognostic significance in a series of 70 patients with childhood medulloblastoma.…”

Section: Discussionmentioning

confidence: 99%

Calbindin‐D_28k

Pelc¹,

Vincent

Ruchoux

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe expression of the Ca2+‐binding protein calbindin‐D28k was analyzed in medulloblastomas in relation to clinical features and other biologic markers related to cell proliferation, differentiation, p53, and cerebellar developmental regulated gene expression.METHODSImmunohistochemistry was carried out on histologic slides from a first retrospective series of 29 nonmetastatic and 10 metastatic medulloblastoma formalin‐fixed, paraffin‐embedded tissues, using specific antibodies against calbindin‐D28k, calretinin, α‐parvalbumin and β‐parvalbumin, and S100 proteins. Informed consent was obtained from the subjects and/or guardians. Other biologic markers for differentiation, cell proliferation, the expression of the p53 tumor suppressor gene protein, and cerebellar developmental regulated genes were similarly investigated. A second series of 16 medulloblastomas from young patients (younger than 15 years) was added in order to validate the results obtained in the first series.RESULTSOf all the markers investigated, only calbindin‐D28k was significantly associated with prognosis. Survival and remission (i.e. recurrence free) time analysis performed on all the cases (n = 55) confirmed a high risk of death (P = 0.004) and recurrence (P = 0.003) associated with calbindin‐positivity. As calbindin‐positivity was predominantly observed in tumors from young patients, the authors confirmed its prognostic value in the subgroup of patients younger than 15 years (n = 37). Cox regression analysis showed a significant and independent prognostic value for calbindin expression and, to a lesser extent, the type of surgery (total or subtotal). Three risk groups were thus identified, distinguishing among the cases characterized by a total resection and calbindin‐negativity (good prognosis), by a subtotal resection and calbindin‐negativity (intermediary), and by calbindin‐positivity (bad prognosis).CONCLUSIONSThe current study suggests that calbindin‐positive medulloblastomas represent a subclass of aggressive tumors more frequently seen in younger patients. Cancer 2002;95:410–9. © 2002 American Cancer Society.DOI 10.1002/cncr.10666

show abstract

Section: Discussionmentioning

confidence: 99%

Calbindin‐D_28k

Pelc¹,

Vincent

Ruchoux

et al. 2002

Cancer

View full text Add to dashboard Cite

show abstract

“…Neuronal differentiation in MBs is usually incipient in that neuronal immunohistochemical markers can detect it, although ganglion cells and "ganglioid" cells are rarely seen. Synaptophysin is mostly immunoreactive, especially in fibrillary cores of HomerWright rosettes and intranodular fibrillary areas of pale islands in desmoplastic MBs, with reported positivity varying from 70% to 100% (Maraziotis et al 1992;McLendon et al 1999;Min et al 2006). MAP-2 mirrors synaptophysin, although not as specific to cells with neuronal differentiation as synaptophysin, but shows a more intense granular or punctate pattern of reactivity.…”

Section: Medulloblastomamentioning

confidence: 99%

Diagnosing and Grading of Brain Tumors: Immunohistochemistry

Takei

Powell

2010

Methods of Cancer Diagnosis, Therapy, and Prognosis

View full text Add to dashboard Cite

“…La histología clásica muestra que son tumores altamente vascularizados con núcleos ovales o redondos, hipercromáticos, nucleolos prominentes y poca diferenciación citoplásmica. Las figuras mitóticas son abundantes y puede haber focos de hemorragia y necrosis 23,24 .…”

Section: Histopatologíaunclassified

“…Un estudio de ciindican diferenciación neuroblástica) hasta en el 40% de los casos. Aunque a simple vista puede verse una pseudocápsula, microscópicamente se observan células que invaden el cerebro y a menudo se extienden a las leptomeninges y al espacio subaracnoideo 23,24 .…”

Section: Extensión De La Enfermedadunclassified

“…La diferenciación astrocítica, evidenciada por la inmunorreactividad para la proteína fibrilar glial ácida, puede ser vista en hasta el 50% de los meduloblastomas 23 . La tinción positiva para β-catenina está presente en la mayoría de los tumores de la vía WNT, al igual que puede encontrarse tinción positiva para p53 en los tumores que tienen esta mutación 24 .…”

Section: Extensión De La Enfermedadunclassified

See 1 more Smart Citation

Meduloblastoma: de la clasificación histológica a la molecular

Pabón

Hoyos

Restrepo

et al. 2018

MedUPB

View full text Add to dashboard Cite

RESUMENEl meduloblastoma es un tumor frecuente en la población pediátrica, pero es raro en pacientes adultos. Es la segunda causa de muerte por cáncer en menores de 15 años. El hallazgo de una lesión tumoral cerebelosa mediana o paramediana que capta el medio de contraste y que a menudo comprime el cuarto ventrículo sugiere la presencia de este tumor. A través del uso de estudios de expresión génica y marcadores moleculares se ha generado una nueva aproximación a la clasificación del meduloblastoma. Así, se ha venido a entender el concepto de meduloblastoma no como una patología sino como un grupo de patologías distintas clínica y molecularmente. La resonancia magnética nuclear espinal y la punción lumbar deben ser realizadas en todos los pacientes como parte de la evaluación de la extensión de la enfermedad, debido a que las leptomeninges espinales son un sitio frecuente de diseminación. El tratamiento implica idealmente la interacción de un grupo interdisciplinario que pueda ofrecer al paciente: cirugía, radioterapia y quimioterapia. El pronóstico depende de variables como edad (menor de tres años), diseminación de la enfermedad, residuo tumoral posquirúrgico, variante histológica de células grandes/anaplásico, y pertenecer al grupo 3 (grupo de amplificacón del MYC).Palabras clave: cerebelo; meduloblastoma; expresión génica; clasificación. ABSTRACTMedulloblastoma is a common tumor in children, but is rare in adults. It is the second most common cause of cancer-related death in patients under 15 years. The presence of a median or paramedian enhancing cerebellar mass, often compressing the fourth ventricle may indicate the presence of this tumor. Genetic and molecular markers offer a new approach to the understanding and classification of medulloblastomas. Hence, we have come to understand medulloblastoma not as a sole disease but rather, as a group of clinically and molecularly distinct pathologies. Magnetic resonance imaging of the spine and lumbar puncture must be performed in all patients as part of the assessment of the extent of disease, since spinal leptomeninges are common sites for metastatic dissemination. Ideally, its treatmeant involves an interdisciplinary group that provides surgery, radiotherapy, and chemotherapy. Prognosis depends upon variables such as age (under three years), metastatic dissemination, residual tumor after surgery, large cell/ anaplastic histological variant, and group 3 tumor (MYC amplification group).

show abstract

Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study

Abstract: Immunohistochemistry is a useful adjunct in characterizing subsets of paediatric medulloblastomas and confirms that larger co-operative studies may be fruitful in identifying a prognostic utility of a combined histochemical/immunohistochemical analysis on these tumours.

Cited by 38 publications

References 48 publications

Calbindin‐D_28k

Calbindin‐D_28k

Diagnosing and Grading of Brain Tumors: Immunohistochemistry

Meduloblastoma: de la clasificación histológica a la molecular

Contact Info

Product

Resources

About

Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study

Abstract: Immunohistochemistry is a useful adjunct in characterizing subsets of paediatric medulloblastomas and confirms that larger co-operative studies may be fruitful in identifying a prognostic utility of a combined histochemical/immunohistochemical analysis on these tumours.

Cited by 38 publications

References 48 publications

Calbindin‐D28k

Calbindin‐D28k

Diagnosing and Grading of Brain Tumors: Immunohistochemistry

Meduloblastoma: de la clasificación histológica a la molecular

Contact Info

Product

Resources

About

Calbindin‐D_28k

Calbindin‐D_28k